Rp11-362k2.2:Rp11-767i20.1 genetic variation is associated with post-reperfusion therapy parenchymal hematoma. a gwas meta-analysis

Elena Muiño, Jara Cárcel-Márquez, C. Carrera, Laia Llucià-Carol, Cristina Gallego-Fabrega, Natalia Cullell, Miquel Lledós, J. Castillo, T. Sobrino, Francisco Campos, E. Rodríguez-Castro, M. Millán, L. Muñoz-Narbona, Alejandro Bustamante, E. López-Cancio, M. Ribó, José Álvarez Sabín, J. Jiménez-Conde, J. Roquer, Eva Giralt SteinhauerC. Soriano-Tárraga, C. Vives-Bauza, R. Díaz Navarro, S. Tur, V. Obach, Juan F.. Arenillas, T. Segura, G. Serrano-Heras, Joan Martí-Fàbregas, Raquel Delgado Mederos, Pol Camps-Renom, Luis Antonio Prats-Sánchez, Daniel Guisado-Alonso, Marina Guasch-Jiménez, Rebeca Marin, Alejandro Martínez-Domeño, M.D.M. Freijo-Guerrero, F. Moniche, Juan Antonio Cabezas, M. Castellanos, J. Krupinsky, D. Strbian, T. Tatlisumak, V. Thijs, R. Lemmens, A. Slowik, J. Pera, Laura Heitsch, Laura Ibañez, Carlos Cruchaga, R. Dhar, J.M. Lee, J. Montaner, Israel Fernandez-Cadenas

Producció científica: Contribució a revistaArticleRecercaAvaluat per experts

9 Cites (Scopus)

Resum

Stroke is one of the most common causes of death and disability. Reperfusion therapies are the only treatment available during the acute phase of stroke. Due to recent clinical trials, these therapies may increase their frequency of use by extending the time-window administration, which may lead to an increase in complications such as hemorrhagic transformation, with parenchymal hematoma (PH) being the more severe subtype, associated with higher mortality and disability rates. Our aim was to find genetic risk factors associated with PH, as that could provide molecular targets/pathways for their prevention/treatment and study its genetic correlations to find traits sharing genetic background. We performed a GWAS and meta-analysis, following standard quality controls and association analysis (fastGWAS), adjusting age, NIHSS, and principal components. FUMA was used to annotate, prioritize, visualize, and interpret the meta-analysis results. The total number of patients in the meta-analysis was 2034 (216 cases and 1818 controls). We found rs79770152 having a genome-wide significant association (beta 0.09, p-value 3.90 × 10) located in the RP11-362K2.2:RP11-767I20.1 gene and a suggestive variant (rs13297983: beta 0.07, p-value 6.10 × 10) located in PCSK5 associated with PH occurrence. The genetic correlation showed a shared genetic background of PH with Alzheimer's disease and white matter hyperintensities. In addition, genes containing the ten most significant associations have been related to aggregated amyloid-β, tau protein, white matter microstructure, inflammation, and matrix metalloproteinases.
Idioma originalAnglès
RevistaJournal of Clinical Medicine
Volum10
Número14
DOIs
Estat de la publicacióPublicada - 2021

Fingerprint

Navegar pels temes de recerca de 'Rp11-362k2.2:Rp11-767i20.1 genetic variation is associated with post-reperfusion therapy parenchymal hematoma. a gwas meta-analysis'. Junts formen un fingerprint únic.

Com citar-ho